Gilbert, AZ8 Active Studies

Lung Cancer Clinical Trials in Gilbert, AZ

Find 8 actively recruiting lung cancer clinical trials in Gilbert, AZ. Connect with local research sites and explore new treatment options.

8
Active Trials
6
Sponsors
4,546
Enrolling

Recruiting Lung Cancer Studies in Gilbert

RecruitingGilbert, AZNCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by...

1,210 participants
National Cancer Institute (NCI)
View Study Details
RecruitingGilbert, AZNCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated ad...

1,016 participants
Eli Lilly and Company
View Study Details
RecruitingGilbert, AZNCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want ...

680 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingGilbert, AZNCT06564844

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgic...

660 participants
AstraZeneca
View Study Details
RecruitingGilbert, AZNCT04165070

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-04...

450 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingGilbert, AZNCT06497556

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12...

320 participants
Hoffmann-La Roche
View Study Details
RecruitingGilbert, AZNCT04938817

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1...

110 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingGilbert, AZNCT04367311

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy. However, relapse rates remain high...

100 participants
Nasser Hanna
View Study Details

About Lung Cancer Clinical Trials in Gilbert

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 8 lung cancer clinical trials recruiting participants in Gilbert, AZ. These studies are seeking a combined 4,546 participants. Research is being sponsored by National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Gilbert — FAQ

Are there lung cancer clinical trials in Gilbert?

Yes, there are 8 lung cancer clinical trials currently recruiting in Gilbert, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Gilbert?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Gilbert research site will contact you about next steps.

Are clinical trials in Gilbert free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Gilbert studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 8 active trials in Gilbert are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated March 2, 2026 from ClinicalTrials.gov